Study Country N F/U (mo) eGFR (ml/min) Protein- uria (g/d) Nephrotic (%) Immuno- suppression (%) Segmental Sclerosis (%) Tubular atrophy/ Interstitial fibrosis (>25%) (%) Arterio- sclerosis (%) C3 deposit  (%) EM stage≥3  (%) EM type heterogeneous (%) Renal failure (%) ESRD (%) Zuo 2013 China 217 74 110 3.9 139 (64) 121 (56) - - - - - - 24 (12) G 10 (5) Sprangers 2012 USA 132 A 68 77 9.0 92 (70) 98 (74) 24 (21) 23 (20) 90 (77) - 33 (33) -  36 (27)H 9 (7) Horvatic 2012 Croatia 60 48 75 7.7 56 (93) 51 (85) 34 (57) - D 33 (55) 53 (88) 26 (43) 31 (52) 12 (20) I - Eriguchi 2009 Japan 103 102 72 6.9 103 (100) 103 (100) 28 (27) 31 (30)E 52 (50) - 36 (35) - 12 (12) J 4 (4) Heeringa 2007 Netherlands 53 62 85 7.0 53 (100) 20 (38) 22 (42) 33 (62) - - 16 (30) - 24 (45) I 6 (11) Troyanov 2006 Canada 389 58 76 4.7 348 (89) 220 (57) 97 (25) 70 (18) 210 (54) 264 (68) 222 (57) 202 (52) - 50 (13) Yoshimoto 2004 Japan 105 116 96 - 75 (71) 88 (84) - - - - - 45 (43) - 12 (11) Shiiki 2004 Japan 949 B 83 90 (10) C >3.5 949 (100) 788 (83) 29 (5) 54 (9) F 222 (38) - 111 (18) - 79 (8) K 47 (5) Dumoulin 2003 France 72 48 88 7.1 61 (85) 33 (46) 30 (42) 47 (65) 28 (39) - 13 (18) - 27 (38) L 18 (25) A: 117 of 132 patients (89%) were available for light microscopic evaluation; B: 578 of 949 patients (61%) were available for light microscopic evaluation and 610 of 949 (64%) patients were available for electronic microscopic evaluation; C: 90 of 949 (10%) patients had baseline serum creatinine ≥ 1.5 mg/dl; D: the cut-off value was 18%; E: the cut-off value was 10%; F: the cut-off value was 20%; G: eGFR <60 ml/min per 1.73 m2; H: doubling of serum creatinine; I: ≥50% increase of eGFR or death; J: serum creatinine >1.5 mg/dl or >50% increase from baseline value; K: serum creatinine >3.0 mg/dl; L: serum creatinine >1.7 mg/dl.

Table 1: Clinical and pathological features, immunosuppression, and renal outcomes of nine included studies.